Skip to content

US · WGS · MEDICAL - HEALTHCARE INFORMATION SERVICES

GeneDx Holdings Corp. (WGS) intrinsic value and stock valuation

$45.46as of 2026-11-21 · Mkt cap 2.3B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

GeneDx Holdings Corp. DCF and intrinsic value

InvestorsCraft values WGS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from WGS’s statements →

GeneDx Holdings Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Healthcare Information Services Stamford, CT 06902 genedx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$427.5M+19% 5y CAGRd
20192025
Net income
-$-21.02M
20192025
Free cash flow
$14.3M
20192025
Total equity
$308.2M+134% 5y CAGRd
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$427.5M$305.5M$202.6M$234.7M$212.2M
Operating income-$-11.8M-$-23.21M-$-180.6M-$-667.65M-$-446.15M
Net income-$-21.02M-$-52.29M-$-175.77M-$-548.98M-$-245.39M
EPSd-$-781.7K-$-1.94M-$-7.23M-$-53.61M-$-74.81M
Operating cash flow$33.3M-$-28.5M-$-180.15M-$-319.15M-$-190.43M
Capital expenditure-$-19.02M-$-5.49M-$-5.71M-$-14.32M-$-20.79M
Free cash flow$14.3M-$-33.99M-$-185.86M-$-333.48M-$-211.22M
Total assets$570.2M$419.4M$418.8M$545.3M$554.1M
Total debt$152M$116.2M$119.8M$77.1M$32.9M
Net debt$47M$31M$20.1M-$-60.27M-$-367.72M
Total equity$308.2M$245.3M$228M$253.7M$388.1M
Cash and short-term investments$171.3M$141.2M$130.2M$137.4M$400.6M
Income statement
20252024202320222021
Revenue$427.5M$305.5M$202.6M$234.7M$212.2M
Cost of revenue$129.4M$111.1M$112.6M$261.4M$228.8M
Gross profit$298.2M$194.4M$90M-$-26.75M-$-16.6M
Research and development expenses$72M$45.7M$58.3M$86.2M$105.2M
Selling, general and administrative expenses$239.2M$168.5M$194.7M$338.2M$318.7M
Other expenses$0.00$3.41M$17.6M$216.5M$5.66M
Operating expenses$311.3M$217.6M$270.6M$640.9M$429.6M
Cost and expenses$439.3M$328.7M$383.2M$902.4M$658.3M
Interest income$0.00$0.00$1.11M$2.54M$80K
Interest expense$2.54M$3.03M$0.00$3.21M$2.83M
Depreciation and amortization$25.2M$22M$33.7M$59.3M$21.8M
Ebitda$6.63M-$-27.64M-$-136.46M-$-398.2M-$-220.75M
Operating income-$-11.8M-$-23.21M-$-180.6M-$-667.65M-$-446.15M
Total other income/expenses, net-$-9.34M-$-29.42M$3.9M$69.6M$200.8M
Income before tax-$-21.14M-$-52.63M-$-176.69M-$-598.03M-$-245.39M
Income tax expense-$-120K-$-340K-$-930K-$-49.05M$0.00
Net income-$-21.02M-$-52.29M-$-175.77M-$-548.98M-$-245.39M
Weighted average shares outstanding$26.9M$26.9M$24.3M$10.2M$3.28M
Weighted average diluted shares outstanding$26.9M$26.9M$24.3M$10.2M$3.28M
Balance sheet
20252024202320222021
Cash and short-term investments$171.3M$141.2M$130.2M$137.4M$400.6M
Net receivables$74.4M$37.6M$32.8M$43.3M$26.6M
Inventory$14M$10.7M$8.78M$13.7M$33.5M
Total current assets$268.3M$198M$182.3M$212.6M$483.5M
Property, plant and equipment, net$69.1M$58.5M$59.4M$84.3M$62.7M
Goodwill and intangible assets$182M$158.6M$172.6M$186.7M$0.00
Long-term investments$0.00$0.00$0.00$900K$900K
Total non-current assets$301.9M$221.4M$236.4M$332.6M$70.6M
Total assets$570.2M$419.4M$418.8M$545.3M$554.1M
Accounts payable$2.46M$7.95M$10.2M$46M$44.7M
Short-term debt$8.95M$3.34M$4.14M$10.9M$3.42M
Deferred revenue$0.00$0.00$0.00$40K$470K
Total current liabilities$108.9M$54.8M$58.8M$144.3M$101.3M
Long-term debt$143M$112.8M$115.6M$66.3M$29.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$153.1M$119.3M$131.9M$147.3M$64.7M
Capital lease obligations$56.1M$64.3M$66.6M$60M$18.4M
Total liabilities$262M$174.1M$190.7M$291.6M$166M
Common stock$0.00$0.00$0.00$40K$20K
Retained earnings-$-1.37B-$-1.35B-$-1.3B-$-1.12B-$-575.44M
Accumulated other comprehensive income (loss)$940K$830K$420K$0.00$0.00
Total equity$308.2M$245.3M$228M$253.7M$388.1M
Total investments$66.3M$56M$30.5M$900K$900K
Total debt$152M$116.2M$119.8M$77.1M$32.9M
Net debt$47M$31M$20.1M-$-60.27M-$-367.72M
Cash flow statement
20252024202320222021
Net income-$-21.02M-$-52.29M-$-175.77M-$-548.98M-$-245.39M
Depreciation and amortization$25.2M$22M$35.8M$59.3M$21.8M
Stock-based compensation$32.2M$9.14M-$-330K$42M$219.4M
Change in working capital-$-15.6M-$-24.75M-$-38.24M$36.1M$8.08M
Accounts receivable-$-36.23M-$-5.42M$10.3M$5.53M$5.54M
Inventory-$-3.44M-$-2.58M$970K$4.6M-$-10.62M
Accounts payable$12.1M-$-20.46M-$-46.95M$34.5M$0.00
Net cash provided by operating activities$33.3M-$-28.5M-$-180.15M-$-319.15M-$-190.43M
Investments in property, plant and equipment-$-19.02M-$-5.49M-$-5.71M-$-14.32M-$-9.4M
Acquisitions, net-$-32.86M$0.00-$-8.11M-$-127M$0.00
Net cash used for investing activities-$-61.52M-$-30.13M-$-43.73M-$-141.33M-$-20.79M
Common stock issued$51.7M$46.5M$143M$197.7M$442.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$48M$44.2M$186.2M$197.3M$493.7M
Net change in cash$19.8M-$-14.47M-$-37.72M-$-263.17M$282.5M
Cash at end of period$106M$86.2M$99.7M$138.3M$401.5M
Operating cash flow$33.3M-$-28.5M-$-180.15M-$-319.15M-$-190.43M
Capital expenditure-$-19.02M-$-5.49M-$-5.71M-$-14.32M-$-20.79M
Free cash flow$14.3M-$-33.99M-$-185.86M-$-333.48M-$-211.22M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About GeneDx Holdings Corp.

        GeneDx Holdings Corp. functions as a health intelligence firm singularly focused on the individual patient. It aims to revolutionize healthcare delivery by deploying advanced artificial intelligence and machine learning capabilities. These sophisticated algorithms are applied to vast, longitudinal clinical and genomic datasets to construct comprehensive, dynamic models of human health, ultimately defining personalized, optimal pathways for each person's well-being. Through its exclusive Centrellis health intelligence platform, the company gains profound insights into both disease states and overall wellness, enabling it to furnish evidence-based solutions for the most critical medical challenges. Eric Schadt established the corporation in October 2015, and its principal offices are located in Stamford, Connecticut.

        CEO
        Katherine A. Stueland
        Employees
        1.3K
        Beta
        1.91

        Explore

        Frequently asked questions

        What is the intrinsic value of GeneDx Holdings Corp. (WGS)?

        GeneDx Holdings Corp. (WGS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is WGS undervalued?

        WGS trades at a price of $45.46 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.